The standard clinical practice of 2mg, 30 minutes before bed was compared against an optimized protocol of 4mg, taken 3 hours earlier. The optimized protocol outperformed across sleep onset and total sleep time metrics
He oversees the IV therapy program and personally approves formulary changes
Description IGF-1 LR3 (Long [Arg] Insulin-like Growth Factor-1) is a recombinant synthetic analog of human insulin-like growth factor 1, engineered with two structural modifications: an arginine substitution replacing glutamate at position 3 of the IGF-1 sequence (reducing IGFBP-3 binding affinity), and a 13-amino-acid N-terminal extension (Long peptide leader)
Safety, Risks, and Contraindications Known and potential adverse effects of SubQ gluathione include: Injection site reactions: redness, swelling, induration (for a full breakdown of whats normal versus what requires attention, see my article about peptide injection site reactions) Skin rashes Rare but serious: Stevens-Johnson syndrome has been reported in case studies linked to injectable glutathione use IV glutathione has triggered bronchospasm in asthma patients
Biotinoyl tripeptide-1 stimulates production of laminin-5 and collagen IV, two proteins essential for follicle structure
Direct oxidation of GSH to GSH through free radical intermediates formed from 15-HpETE-PE before it is metabolized could also occur
